OLMA Olema Pharmaceuticals, Inc. Insider Trading

CLO Mitchell Shawnte sells entire 40,000-share stake in OLMA for $951.5K across 3 transactions (Mar 3-4)

Mitchell Shawnte, Chief Legal Officer, liquidated his entire 40,000-share position in Olema Pharmaceuticals through three separate sales on March 3-4, 2026, realizing $951,502.52 at a blended average price of $23.79. The complete exit is notable given that the stock now trades at $22.56, down 37.0% from its 52-week high and down 13.7% over the prior 30 days. Olema is currently unprofitable with net income of $-42,217,000.00 for its most recent full fiscal year, and the company's market cap of $1,548,967,862.88 reflects a biotech firm in burn-down mode. A C-suite legal officer's total divestment removes a meaningful information asymmetry holder from the cap table, particularly at a company facing negative profitability and recent equity price deterioration.

CFO Kovacs sells 103,822 shares ($3.0M) across 2 transactions; stock down 14.8% in 30 days amid $-42.2M annual loss

Kovacs Shane William Charles, Chief Operating & Financial Officer, executed 2 separate sales totaling 103,822 shares for $2,980,054.22, reducing his holdings by 42.6% from 243,549 to 139,727 shares. The transactions occurred at blended average price of $28.70, within the stock's recent downtrend: the current price of $29.19 reflects a 14.8% decline over the prior 30 days and sits 18.5% below the 52-week high of $35.83. The company reported net income of $-42,217,000.00 for its most recent full fiscal year, signaling ongoing unprofitability. A substantial near-half reduction in an executive's stake during deteriorating near-term price momentum warrants attention to company fundamentals and near-term outlook.

Chief Discovery Officer Myles David C. sells 110,000 shares (16.9% of holdings) across 5 transactions for $3.1M at blended average $28.25

Myles David C., Chief Discovery and Non-Clinical Development Officer, executed 5 separate sales totaling 110,000 shares (110.0K shares) for $3,107,229.17 over three trading days (Jan 12-14, 2026) at prices ranging from $27.60 to $28.99, with a blended average price of $28.25. This represents a 16.9% reduction in his pre-transaction holdings of 652,761 shares, leaving him with 542,761 shares post-transaction. The sales occurred while the stock has declined 19.7% from its 52-week high of $35.83 and is currently trading at $28.77, near the lower end of the transaction range. Notably, Olema is unprofitable with a net loss of $42,217,000.00 over its most recent full fiscal year, providing operational context for insider liquidity activity. Prior trades by this insider at OLMA (three sells on 2025-12-19) have insufficient measurable history to assess timing patterns at this specific ticker.

Chief Discovery Officer sells 51,000 OLMA shares for $1.6M at $30.46 avg; retains 542.9K shares post-transaction.

Myles David C., Chief Discovery Officer, executed 3 separate sales totaling 51,000 shares for $1,553,543.54 at a blended average price of $30.46 on 2025-12-19. The shares were sold across three tranches at prices ranging from $28.08 to $31.39, representing an 8.6% reduction from his pre-transaction holdings of 593.9K shares. Notably, the transaction occurred when the stock was trading at $27.67, approximately 9% below the blended sale price, and 22.8% below its 52-week high of $35.83. The company remains unprofitable with a full-year net income of $-42.2M, while the insider retained substantial holdings of 542.9K shares post-transaction, suggesting continued material exposure to the company despite the sale.

Director Clark sold 264.8K shares (entire holding) at blended $29.73, generating $7.9M; exits to zero post-transaction

Ian T Clark, a director at Olema Pharmaceuticals, executed 3 separate sales on 2025-12-19 totaling 264,800 shares for $7,873,109.28, representing a complete liquidation of his shareholding (pre-transaction: 264,800 shares; post-transaction: 0 shares). The blended average price of $29.73 compares to a current price of $27.67, positioning the sales above the present market level. Olema is trading at -22.8% from its 52-week high of $35.83 and the company reported negative net income of $-42,217,000.00 over its most recent full fiscal year. The complete elimination of his equity stake—coupled with the company's unprofitability and the director's prior track record of 3 open-market sales across all tickers—represents a material change in insider positioning and warrant deeper examination into the context and timing of this comprehensive exit.

CMO Zojwalla Naseem sold 269,509 shares for $7,530,147.84 across 4 sales, reducing stake by 98.4% at unprofitable firm.

Zojwalla Naseem, Chief Medical Officer of Olema Pharmaceuticals, executed 4 separate sales totaling 269,509 shares for $7,530,147.84 between December 19–23, 2025, at prices ranging from $27.66 to $28.93 (blended average $27.94). Post-transaction holdings dropped to 4,488 shares, representing a 98.4% reduction in his position from 273,997 shares held prior. This near-complete liquidation occurs as the company faces material headwinds: Olema reported net income of $-42,217,000.00 for its most recent full fiscal year, making it unprofitable. The company's stock is currently trading at $27.67, down 22.8% from its 52-week high of $35.83. The concentration and scale of this exit—divesting nearly the entire stake—stands in sharp contrast to the stock's 30-day (+19.4%) and 90-day (+231.4%) gains, which would otherwise suggest near-term momentum.

Bain Capital Life Sciences (10% owner) purchases 300,000 OLMA shares at $5.76; stock down 70.9% from 52-week high, firm unprofitable.

Bain Capital Life Sciences Investors, LLC, a 10% stakeholder in Olema Pharmaceuticals, purchased 300,000 shares at $5.76 on 2025-01-08, increasing holdings by 7.5% to 4,300,000 shares and deploying $1,727,370.00 in capital. The timing occurs after substantial deterioration: the stock is at $4.84 (current price), representing a 70.9% decline from the 52-week high of $16.62 and a 58.4% drop over the past 90 days. The company posted net income of $-34,555,000.00 for its most recent full fiscal year. Across the insider's cross-ticker track record, 2 prior open-market buys averaged a 90-day return of +2.6% with a 50% win rate, providing limited predictive signal for this position. The material investment by a substantial existing shareholder during a period of sharply depressed valuation warrants monitoring for what it may signal about the insider's own confidence in the asset's prospects or strategic position.

Director Walmsley sold and bought 700,761 shares at $6.75 simultaneously on 2024-12-17; stock down 33.0% in 30 days.

Graham G. Walmsley, a Director at Olema Pharmaceuticals, executed 2 offsetting transactions on 2024-12-17: a sale of 700,761 shares at $6.75 for $4,730,136.75 and an immediate purchase of 700,761 shares at $6.75 for $4,730,136.75. This simultaneous buy-sell at the same price and volume suggests a technical or tax-motivated transaction rather than a market conviction signal. The company reported net income of $-34,555,000.00 over its most recent full fiscal year and trades at $6.14 today, down 33.0% over the past 30 days and 52.1% over 90 days. While Walmsley's prior OLMA trades show mixed timing (3 of 5 well-timed at the 90-day mark), his cross-ticker track record shows 2 prior sells with a 100.00% well-timed rate, though the stock has declined sharply since this filing date. The offsetting nature of this transaction and the unprofitable fundamentals warrant examination of the underlying mechanics and context.

CEO Sean Bohen sells 109.5K shares (31.2% of holdings) across 3 trades at blended avg $9.01; stock down 49.4% from 52-week high, company unprofitable.

Sean Bohen, President and CEO, executed 3 separate sales totaling 109,502 shares for $986,365.11 at an average of $9.01 per share on December 10–11, 2024, reducing his holdings by 31.2%. The transactions occurred as Olema's stock trades at $8.41, down 49.4% from its 52-week high of $16.62 and down 33.9% over the past 30 days—a period of severe price deterioration. Against this backdrop, the company reported a net loss of $34,555,000 for its most recent full fiscal year, reflecting ongoing unprofitability. While Bohen's cross-ticker sell track record shows a 33.33% well-timed rate with a positive average 90-day return of +0.7%, his prior trades specifically at OLMA show mixed timing results (1 of 3 well-timed at the 90-day mark). The combination of a large liquidation by the CEO, sustained stock decline, and negative fundamentals merits investor attention to assess whether this reflects a loss of confidence in near-term prospects or capital reallocation.

10% owner Paradigm Biocapital sells 2,400,000 shares (75.4% of stake) at $14.92, reducing holding to 783.1K shares

Paradigm Biocapital Advisors LP, a 10% stakeholder, executed 2 separate sales totaling 2,400,000 shares for $35,796,000.01 at a blended average price of $14.92 on August 1, 2024, liquidating three-quarters of its position from 3,183,118 shares to 783,118 shares. This represents a substantial reduction in concentrated ownership during a period of recovery in OLMA's stock—the company trades at $13.87, up 30.0% over 30 days and 23.4% over 90 days. The sale occurred at a premium to the current price ($14.92 vs. $13.87), though well below the 52-week high of $17.14. Paradigm's prior purchase at this ticker in December 2023 delivered a 90-day return of +19.2%, but this significant liquidation warrants scrutiny regarding institutional confidence in the company's near-term prospects, particularly given OLMA's fundamental position: the company posted a net loss of $-30,970,000.00 over its most recent full fiscal year and remains unprofitable.